GC Biopharma

May 14, 2025

GC Biopharma Receives FDA Approval for its U.S. Plasma Collection Center in Calexico, California

Apr 09, 2025

GC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine

Feb 11, 2025

GC Biopharma Shares Research Updates on Rare Disorder Drugs at the WORLD Symposium 2025

Nov 25, 2024

GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment

Oct 28, 2024

GC Biopharma and Novelty Nobility Enter into Joint Research and Development Agreement for Geographic Atrophy Therapies

Jun 10, 2024

FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A

Jun 04, 2024

GCBP Sponsors 2024 Spring Symposium for KASBP and Present Research Findings

May 21, 2024

GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance

May 20, 2024

GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval

Jan 22, 2024

European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A)